(2S)-2-(4-bromophenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester | 769944-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (2S)-2-(4-bromophenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester
• 英文别名: (S)-2-(4-bromophenyl)-1,4-di(t-butoxycarbonyl)piperazine；ditert-butyl (2S)-2-(4-bromophenyl)piperazine-1,4-dicarboxylate
• CAS: 769944-85-6
• 化学式: C₂₀H₂₉BrN₂O₄
• 分子量: 441.365
• InChiKey: LMMOHMLJBDPFAH-MRXNPFEDSA-N

物化性质

• 沸点：
  484.8±45.0 °C(Predicted)
• 密度：
  1.285±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S)-2-(4-bromophenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester 在 盐酸 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 (2S)-2-(4-bromophenyl)piperazine
  参考文献：
  名称：

  [EN] 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS
  [FR] COMPOSE PYRIMIDONE

  摘要：

  公开号：

  WO2006036015A3
• 作为产物：
  描述：

  (R)‑2‑bromo‑1‑(4′‑bromophenyl)ethanol 在 氯化亚砜 、 sodium azide 、 硼烷四氢呋喃络合物 、 1-氯乙基氯甲酸酯 、 三乙胺 、 三苯基膦 、 potassium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 Petroleum ether 为溶剂， 生成 (2S)-2-(4-bromophenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester
  参考文献：
  名称：

  Asymmetric synthesis of 2-arylpiperazines

  摘要：

  An asymmetric synthesis of 2-arylpiperazines starting from phenacyl bromides, a variety of which are easily available, has been established. The synthesis features a CBS reduction of phenacyl bromide to provide optically enriched compounds, an S(N)2 reaction of 1,2,3-oxathiazolidine 2-oxides with an azide anion with invert of configuration, and construction of the piperazine ring via reduction of piperazine-2,3-diones. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.047

文献信息

• [EN] 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES<br/>[FR] DERIVES DE 2,3,6-TRISUBSTITUE 4-PYRIMIDONE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004085408A1

  公开（公告）日：2004-10-07

  A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.

  一种具有tau蛋白激酶1抑制活性的嘧啶酮衍生物，其由化学式（I）或其盐、溶剂合物或水合物表示；用于预防和/或治疗神经退行性疾病（例如阿尔茨海默病）；其中Q代表CH或氮原子；R代表C1-C12烷基基团；化学式（I）的环：代表哌嗪环或哌啶环；每个X独立地代表C1-C8烷基基团、可选择性部分氢化的C6-C10芳环、茚环或类似物；m代表1到3的整数；每个Y独立地代表卤素原子、羟基、氰基、C1-C6烷基基团或类似物；n代表0到8的整数；当X和Y或两个Y基团连接在同一碳原子上时，它们可以结合形成C2-C6烷基基团。
• 2,3,6-Trisubstituted-4-pyrimidone derivatives
  申请人：Watanabe Kazutoshi

  公开号：US20060252768A1

  公开（公告）日：2006-11-09

  A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C 1 -C 12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C 1 -C 8 alkyl group, an optionally partially hydrogenated C 6 -C 10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each independently represents a halogen atom, a hydroxy group, a cyano group, a C 1 -C 6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C 2 -C 6 alkylene group.

  具有tau蛋白激酶1抑制活性的嘧啶酮衍生物，其由式（I）或其盐、溶剂化物或水合物表示; 用于预防和/或治疗神经退行性疾病（例如阿尔茨海默病）等疾病; 其中Q表示CH或氮原子; R表示C1-C12烷基; 公式（I）的环表示哌嗪环或哌啶环; 每个X独立地表示C1-C8烷基，可选部分氢化的C6-C10芳环，茚环或类似物; m表示1至3的整数; 每个独立地表示卤素原子，羟基，氰基，C1-C6烷基或类似物; n表示0至8的整数; 当X和Y或两个Y基附着在同一碳原子上时，它们可以结合形成C2-C6烷基lene基团。
• 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS
  申请人：Watanabe Kazutoshi

  公开号：US20090239864A1

  公开（公告）日：2009-09-24

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R 1 represents a C 1 -C 12 alkyl; R 2 represents a hydrogen atom or the like; R 3 represents a halogen or the like; q represents an integer of 1 to 7; R 4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R 5 represents a C 6 -C 10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I），其手性异构体，或其药学可接受的盐：其中R1表示C1-C12烷基；R2表示氢原子或类似物；R3表示卤素或类似物；q表示1至7的整数；R4表示卤素或类似物；p表示0或1至5的整数；R5表示C6-C10芳基，杂环或类似物；X表示氧，NH或类似物，用于预防和/或治疗由tau蛋白激酶1高活性引起的疾病，例如神经退行性疾病（如阿尔茨海默病）。
• 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08129377B2

  公开（公告）日：2012-03-06

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R1 represents a C1-C12 alkyl; R2 represents a hydrogen atom or the like; R3 represents a halogen or the like; q represents an integer of 1 to 7; R4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R5 represents a C6-C10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I），其手性异构体或药物可接受的盐：其中，R1代表C1-C12烷基；R2代表氢原子或类似物；R3代表卤素或类似物；q代表1至7的整数；R4代表卤素或类似物；p代表0或1至5的整数；R5代表C6-C10芳基，杂环或类似物；X代表氧、NH或类似物，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如神经退行性疾病（例如阿尔茨海默病）。
• 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2261224A2

  公开（公告）日：2010-12-15

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R1 represents a C1-C12 alkyl; R2 represents a hydrogen atom or the like; R3 represents a halogen or the like; q represents an integer of 1 to 7; R4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R5 represents a C6-C10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  由式（I）代表的化合物、其光学活性异构体或其药物可接受盐：其中 R1 代表 C1-C12 烷基；R2 代表氢原子或类似物；R3 代表卤素或类似物；q 代表 1 至 7 的整数；R4 代表卤素或类似物；p 代表 0 或 1 至 5 的整数；R5 代表 C6-C10 芳基、杂环或类似物；X 代表氧、NH 或类似物，用于预防和/或治疗由 tau 蛋白激酶 1 活性亢进引起的疾病，如神经退行性疾病（如阿尔茨海默病）。如阿尔茨海默病）。